Product image of Kexrolt (Atorvastatin, Ezetimibe) supplied by GNH India

Kexrolt

Active Ingredient:
Atorvastatin, Ezetimibe
Origin:
EU

Kexrolt (Atorvastatin, Ezetimibe)

Atorvastatin and Ezetimibe, the active ingredients in Kexrolt, are HMG‑CoA reductase inhibitor and cholesterol absorption inhibitor presented as an oral tablet for adult use. They lower elevated LDL‑cholesterol and total cholesterol in patients with hypercholesterolemia or mixed dyslipidemia.

GNH India supplies Kexrolt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Organonhealthcare Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Kexrolt acts on lipid metabolism to treat several cholesterol‑related disorders.
  • Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels.
  • Mixed dyslipidemia: lowers triglycerides and improves the overall lipid profile.
  • Heterozygous familial hypercholesterolemia: helps patients achieve target LDL‑cholesterol when diet and lifestyle are insufficient.

How It Works

  • Atorvastatin inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, while ezetimibe blocks the NPC1L1 transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. The combined effect produces an additive decrease in circulating LDL‑cholesterol and total cholesterol.

Side Effects

Kexrolt may cause a range of adverse reactions.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Myalgia: muscle aches without weakness.
  • Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea.
  • Elevated liver enzymes: mild transaminase increases.
  • Fatigue: general tiredness.
  • Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

  • Rhabdomyolysis: severe muscle breakdown with dark urine.
  • Acute liver injury: marked elevation of hepatic enzymes or jaundice.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Hepatotoxicity: liver failure in rare cases.
  • Myopathy with weakness: persistent muscle weakness.
  • Renal impairment: secondary to muscle breakdown.

Precautions & Warnings

  • Before starting Kexrolt, consider the following safety measures.
  • Monitor liver function: obtain baseline transaminases and repeat periodically.
  • Assess muscle symptoms: discontinue if severe myalgia, weakness or dark urine develop.
  • Avoid in active liver disease: contraindicated in patients with ongoing hepatic impairment.
  • Use caution with CYP3A4 inhibitors: dose adjustment may be required.
  • Pregnancy: not recommended unless benefits outweigh potential risks.
  • Store at room temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Kexrolt can interact with several medicines; awareness helps prevent adverse events.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure.
  • Gemfibrozil: heightened risk of myopathy and rhabdomyolysis.
  • Cyclosporine: may raise plasma concentrations of both components.
  • Niacin (high dose): additive risk of muscle toxicity.
  • Certain antifungals (e.g., ketoconazole): potentiate statin levels.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect, monitor INR.
  • Digoxin: slight increase in serum levels.
  • Antacids containing aluminum or magnesium: may reduce ezetimibe absorption.
  • Beta‑blockers: monitor for additive lipid‑lowering effect.
  • Fibrates (low dose): watch for muscle-related side effects.

Frequently Asked Questions

Kexrolt is a fixed‑dose combination of atorvastatin and ezetimibe indicated for the treatment of primary hypercholesterolemia, heterozygous familial hypercholesterolemia, and mixed dyslipidemia in adult patients, helping to lower LDL‑cholesterol and total cholesterol when diet and lifestyle changes are insufficient.

Atorvastatin blocks HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, while ezetimibe inhibits the NPC1L1 transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. The dual action produces an additive reduction in circulating LDL‑cholesterol.

The exact dose of Kexrolt is determined by the prescribing clinician based on the patient’s cholesterol profile, cardiovascular risk, and prior therapy. Dosage adjustments are made according to clinical response and tolerability, following local prescribing guidelines.

Safety of Kexrolt in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided in women who are pregnant or planning pregnancy unless specifically advised by a healthcare professional.

To place an order, submit an enquiry on the Kexrolt product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with a statin alone, the addition of ezetimibe in Kexrolt provides an extra 15‑20 % reduction in LDL‑cholesterol by blocking intestinal absorption, which can be valuable for patients who do not reach target levels with statin monotherapy or who require lower statin doses due to tolerability concerns.

Store Kexrolt at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Do not store in bathrooms or near heat sources, and keep the container tightly closed until use.

Kexrolt is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

The most serious adverse events include rhabdomyolysis, a severe muscle breakdown that can lead to kidney injury, and significant liver enzyme elevations indicating possible hepatotoxicity. Patients should report unexplained muscle pain, weakness, dark urine, or jaundice promptly to their healthcare provider.

Kexrolt is contraindicated in individuals with active liver disease, unexplained persistent elevations of hepatic transaminases, known hypersensitivity to atorvastatin, ezetimibe, or any excipients, and in patients taking contraindicated medications such as strong CYP3A4 inhibitors. It should also be avoided in pregnant women unless the benefit outweighs the risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Atorvastatin, Ezetimibe

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT